By subscribing, you accept our Terms & Privacy Policy.
Federal price caps limiting GLP-1 treatments to $350 monthly force pharmaceutical companies to trade premium margins for mass-market volume.
Federal price caps limiting GLP-1 treatments to $350 monthly force pharmaceutical companies to trade premium margins for mass-market volume.
The U.S. leads crude output at 13.2 million barrels a day, but it still relies on foreign sources for 15 vital minerals.
Federal price caps limiting GLP-1 treatments to $350 monthly force pharmaceutical companies to trade premium margins for mass-market volume.
